Qure.NYSE Trend Cloud Study
Updated
uniQuire released some great Potential results from their latest Drugs Evaluation Results.
The markets responded positively. However soon retraced.
Was this just Hype?
The retracement is now down to the FIB 0.318 level.
The latest Market Analysts are showing a huge Upside Potential.
I Will be holding for now.
Your thoughts and Studies for future Upside or Downside is Appreciated.
As always, please get a few outside Expert's Advice before taking Trade or Investment Decisions.
Should you appreciate my Chart Studies, Smash That Rocket Boost Button. It's Just a Click away.
Regards Graham.
The markets responded positively. However soon retraced.
Was this just Hype?
The retracement is now down to the FIB 0.318 level.
The latest Market Analysts are showing a huge Upside Potential.
I Will be holding for now.
Your thoughts and Studies for future Upside or Downside is Appreciated.
As always, please get a few outside Expert's Advice before taking Trade or Investment Decisions.
Should you appreciate my Chart Studies, Smash That Rocket Boost Button. It's Just a Click away.
Regards Graham.
Note
This chart with all the Analyst's Expectations show how our FOMO affects our investment choices. Also possible Market manipulation? So far the experts have got this wrong.
Setting reasonable (+-10% Range I Use) can help one to decide to stay in a Trade or Investment.
Very Choppy markets = indecision
Will get interested if back at FIB 0.2 ish.
Remains very Speculative for great upside.
Keep this one in your High Risk < 2% Capital Strategy Group.
Note
Now at Fib 0.236 Level. Trust this is the Bottom.
I'm a buyer here.
Note
Reversal Seen. Conviction?Note
Almost a 100% Retrace. OMGNote
uniQure Price Target Maintained With a 28.00/Share by Cantor Fitzgerald. Is This Hype?Trade active
JFK Junior appointment is anti VAX.
I'm Out @ Break Even.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.